Elanco Animal Health Incorporated $ELAN Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 794.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 127,928 shares of the company’s stock after buying an additional 113,619 shares during the quarter. SG Americas Securities LLC’s holdings in Elanco Animal Health were worth $2,576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ELAN. Jennison Associates LLC increased its stake in shares of Elanco Animal Health by 322.0% during the second quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after acquiring an additional 2,468,122 shares during the period. Goldman Sachs Group Inc. lifted its position in Elanco Animal Health by 104.5% in the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the period. Primecap Management Co. CA boosted its stake in Elanco Animal Health by 3.1% during the 2nd quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after purchasing an additional 1,543,279 shares in the last quarter. Norges Bank bought a new position in Elanco Animal Health during the 2nd quarter valued at $12,502,000. Finally, Brandes Investment Partners LP increased its position in shares of Elanco Animal Health by 11.3% during the 2nd quarter. Brandes Investment Partners LP now owns 8,100,322 shares of the company’s stock valued at $115,673,000 after purchasing an additional 820,901 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Trading Up 2.3%

Shares of ELAN opened at $24.42 on Wednesday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $24.47. The stock has a market capitalization of $12.13 billion, a P/E ratio of 407.03, a P/E/G ratio of 3.32 and a beta of 1.87. The business’s 50-day moving average price is $22.33 and its 200 day moving average price is $19.50.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.13 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the company posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Activity

In other news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares in the company, valued at approximately $2,688,402.12. This trade represents a 5.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev A. Modi bought 4,500 shares of Elanco Animal Health stock in a transaction dated Thursday, December 11th. The stock was acquired at an average price of $21.33 per share, with a total value of $95,985.00. Following the acquisition, the insider directly owned 123,082 shares of the company’s stock, valued at approximately $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders bought 43,450 shares of company stock worth $937,883. Company insiders own 0.89% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research analyst reports. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, December 10th. Barclays started coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday. Finally, Morgan Stanley increased their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.78.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.